Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 1.03B 895M 831M 767M 1.44B 98.38B 1.47B 9.84B 3.85B 48.86B 3.87B 3.79B 164B P/E 2026 *
-14.7x
P/E 2027 * -12.2x
Enterprise Value 1.03B 895M 831M 767M 1.44B 98.38B 1.47B 9.84B 3.85B 48.86B 3.87B 3.79B 164B EV / Sales 2026 *
27x
EV / Sales 2027 * 51.1x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.65%
1 week+1.52%
Current month-2.71%
1 month-2.71%
3 months+45.03%
6 months+101.29%
Current year+103.04%
1 week 2.16
Extreme 2.16
2.42
1 month 2.04
Extreme 2.04
2.44
Current year 1.1
Extreme 1.1
2.68
1 year 1.01
Extreme 1.0108
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 08/07/2024
Director of Finance/CFO 59 02/01/2025
Chief Tech/Sci/R&D Officer - 01/02/2025
Director TitleAgeSince
Chairman 83 01/01/2005
Chairman 71 27/02/2012
Director/Board Member 67 28/08/2007
Date Insider Type Main position Quantity % Market Cap.
28/02/26 Fiscal year

General Counsel

651,031 0.1792%
28/02/26 Fiscal year

Chief Executive Officer

1,211,357 0.3333%
28/02/26 Fiscal year

Chief Financial Officer

375,355 0.1033%
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%+1.52%+128.92%+16.17% 1.03B
-3.74%-1.56%+45.14%+64.45% 55.2B
-0.81%-0.33%+27.15%+81.12% 55.6B
-10.59%+1.00%-15.51%-14.59% 23.51B
-0.38%-5.46%-3.45%+359.71% 22.35B
-4.01%-2.68%+12.50%-12.70% 20.6B
-1.23%-3.51%+25.70%-31.88% 17.45B
-3.34%-6.96%+22.02%+515.48% 15.16B
-0.49%+0.69%+52.04%+184.30% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
Average -1.78%-1.56%+44.64%+143.43% 23.86B
Weighted average by Cap. -2.06%-0.46%+31.62%+121.92%

Financials

2026 *2027 *
Net sales 38.17M 33.15M 30.78M 28.39M 53.48M 3.64B 54.45M 364M 143M 1.81B 143M 140M 6.09B 20.15M 17.51M 16.26M 14.99M 28.24M 1.92B 28.75M 192M 75.35M 956M 75.68M 74.02M 3.21B
Net income -66.94M -58.14M -53.99M -49.79M -93.79M -6.39B -95.49M -639M -250M -3.17B -251M -246M -10.67B -88.26M -76.66M -71.19M -65.66M -124M -8.43B -126M -843M -330M -4.18B -331M -324M -14.07B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
30/07/26 $2.340 +0.86% 2,140,832
29/07/26 $2.320 -0.85% 2,476,278
28/07/26 $2.340 +4.93% 2,680,219
27/07/26 $2.230 -2.62% 2,957,356
24/07/26 $2.290 -0.43% 1,681,849
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.320USD
Average target price
3.770USD
Spread / Average Target
+62.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock